Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
Not Confirmed
Not Confirmed
09-11 April, 2025
Not Confirmed
Not Confirmed
31 March-01 April, 2025
Plastics Recycling EUPlastics Recycling EU
Not Confirmed
Not Confirmed
01-02 April, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Industry Trade Show
Not Confirmed
09-11 April, 2025
Industry Trade Show
Not Confirmed
31 March-01 April, 2025
Plastics Recycling EUPlastics Recycling EU
Industry Trade Show
Not Confirmed
01-02 April, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/our-unmatched-efficiency-and-track-record-of-faster-dmf-filings-give-our-customers-a-critical-competitive-advantage
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/molecular-glue-degraders-lilly-abbvie-sign-billion-dollar-deals-bms-leads-with-three-late-stage-drugs
10 Jan 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/aileron-therapeutics-announces-rebranding-to-rein-therapeutics-302348094.html
14 Nov 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/aileron-therapeutics-reports-third-quarter-2024-financial-results-and-recent-business-highlights-302306387.html
13 Nov 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/aileron-therapeutics-announces-positive-topline-data-from-cohort-2-of-the-phase-1b-clinical-trial-of-lti-03-in-idiopathic-pulmonary-fibrosis-ipf-302303568.html
31 Oct 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/aileron-therapeutics-and-advancium-health-network-announce-an-exclusive-option-agreement-for-the-acquisition-of-alrn-6924-for-retinoblastoma-302292196.html
12 Oct 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/aileron-therapeutics-to-present-previously-announced-data-from-the-phase-1b-clinical-trial-evaluating-low-dose-lti-03-in-idiopathic-pulmonary-fibrosis-ipf-at-the-22nd-international-colloquium-on-lung-and-airway-fibrosis-302274268.html
23 Sep 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/aileron-therapeutics-completes-enrollment-in-cohort-2-of-the-ongoing-phase-1b-clinical-trial-evaluating-lti-03-in-idiopathic-pulmonary-fibrosis-ipf-302254831.html
Details:
LTI-03, is a novel, synthetic peptide with a dual mechanism targeting alveolar epithelial cell survival as well as inhibition of profibrotic signaling.
Lead Product(s): LTI-03
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: LTI-03
Study Phase: Phase IProduct Type: Peptide
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 13, 2024
Lead Product(s) : LTI-03
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Aileron Announces Positive Data for LTI-03 in Idiopathic Pulmonary Fibrosis
Details : LTI-03, is a novel, synthetic peptide with a dual mechanism targeting alveolar epithelial cell survival as well as inhibition of profibrotic signaling.
Product Name : LTI-03
Product Type : Peptide
Upfront Cash : Inapplicable
November 13, 2024
Details:
Through the acquisition, Advancium will expand its oncology portfolio by acquiring ALRN-6924 (sulanemadlin), which is being evaluated for the treatment of retinoblastoma.
Lead Product(s): Sulanemadlin
Therapeutic Area: Oncology Brand Name: ALRN-6924
Study Phase: PreclinicalProduct Type: Peptide
Sponsor: Advancium Health
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition October 31, 2024
Lead Product(s) : Sulanemadlin
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Advancium Health
Deal Size : Undisclosed
Deal Type : Acquisition
Aileron And Advancium Sign Deal for ALRN-6924 Retinoblastoma Therapy
Details : Through the acquisition, Advancium will expand its oncology portfolio by acquiring ALRN-6924 (sulanemadlin), which is being evaluated for the treatment of retinoblastoma.
Product Name : ALRN-6924
Product Type : Peptide
Upfront Cash : Undisclosed
October 31, 2024
Details:
LTI-03 is a novel, Caveolin-1-related peptide that addresses both inhibition of pro-fibrotic signaling & survival of critical epithelial cells. It is being developed for idiopathic pulmonary fibrosis.
Lead Product(s): LTI-03
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: LTI-03
Study Phase: Phase IProduct Type: Peptide
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 23, 2024
Lead Product(s) : LTI-03
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Aileron Completes Enrollment in Phase 1b Trial of LTI-03 in Pulmonary Fibrosis
Details : LTI-03 is a novel, Caveolin-1-related peptide that addresses both inhibition of pro-fibrotic signaling & survival of critical epithelial cells. It is being developed for idiopathic pulmonary fibrosis.
Product Name : LTI-03
Product Type : Peptide
Upfront Cash : Inapplicable
September 23, 2024
Details:
The proceeds will advance the clinical development of Aileron’s lead candidate, LTI-03, currently in early-stage trials for idiopathic pulmonary fibrosis.
Lead Product(s): LTI-03
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: LTI-03
Study Phase: Phase IProduct Type: Peptide
Sponsor: Titan Partners Group
Deal Size: $40.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering March 05, 2024
Lead Product(s) : LTI-03
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Titan Partners Group
Deal Size : $40.0 million
Deal Type : Public Offering
Aileron Completes $40 Million Underwritten Registered Direct Offering
Details : The proceeds will advance the clinical development of Aileron’s lead candidate, LTI-03, currently in early-stage trials for idiopathic pulmonary fibrosis.
Product Name : LTI-03
Product Type : Peptide
Upfront Cash : Undisclosed
March 05, 2024
Details:
The net proceeds will be used to advance the development of LTI-03, a peptide representing an important region of the Caveolin 1 (Cav1) protein, for the treatment of idiopathic pulmonary fibrosis.
Lead Product(s): LTI-03
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: LTI-03
Study Phase: Phase IProduct Type: Peptide
Sponsor: Titan Partners Group
Deal Size: $4.6 million Upfront Cash: Undisclosed
Deal Type: Public Offering January 05, 2024
Lead Product(s) : LTI-03
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Titan Partners Group
Deal Size : $4.6 million
Deal Type : Public Offering
Positive Initial Data Reported from Immutep's Efti Combined with Radiotherapy in Phase II
Details : The net proceeds will be used to advance the development of LTI-03, a peptide representing an important region of the Caveolin 1 (Cav1) protein, for the treatment of idiopathic pulmonary fibrosis.
Product Name : LTI-03
Product Type : Peptide
Upfront Cash : Undisclosed
January 05, 2024
Details:
LTI-03 is a novel, Caveolin-1-related peptide that addresses both inhibition of pro-fibrotic signaling and survival of critical epithelial cells. Being developed for idiopathic pulmonary fibrosis.
Lead Product(s): LTI-03
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: LTI-03
Study Phase: Phase IProduct Type: Peptide
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 05, 2024
Lead Product(s) : LTI-03
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Aileron Therapeutics Reports Positive Data from Phase 1b Trial Of LTI-03 in IPF
Details : LTI-03 is a novel, Caveolin-1-related peptide that addresses both inhibition of pro-fibrotic signaling and survival of critical epithelial cells. Being developed for idiopathic pulmonary fibrosis.
Product Name : LTI-03
Product Type : Peptide
Upfront Cash : Inapplicable
January 05, 2024
Details:
Aileron intends to use the proceeds primarily to complete the ongoing Phase 1b clinical study of LTI-03, a Caveolin-1-related peptide in development for the treatment of idiopathic pulmonary fibrosis.
Lead Product(s): LTI-03
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: LTI-03
Study Phase: Phase IProduct Type: Peptide
Sponsor: Clear Street LLC
Deal Size: $18.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement October 31, 2023
Lead Product(s) : LTI-03
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Clear Street LLC
Deal Size : $18.0 million
Deal Type : Private Placement
Aileron Therapeutics Announces Acquisition of Lung Therapeutics
Details : Aileron intends to use the proceeds primarily to complete the ongoing Phase 1b clinical study of LTI-03, a Caveolin-1-related peptide in development for the treatment of idiopathic pulmonary fibrosis.
Product Name : LTI-03
Product Type : Peptide
Upfront Cash : Undisclosed
October 31, 2023
Details:
ALRN-6924 is an MDM2/MDMX inhibitor that leverages Aileron’s proprietary peptide drug technology. The primary endpoint of the Phase 1b open-label trial was duration and incidence of severe neutropenia in cycle 1.
Lead Product(s): Sulanemadlin
Therapeutic Area: Dermatology Brand Name: ALRN-6924
Study Phase: Phase IProduct Type: Peptide
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 21, 2023
Lead Product(s) : Sulanemadlin
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ALRN-6924 is an MDM2/MDMX inhibitor that leverages Aileron’s proprietary peptide drug technology. The primary endpoint of the Phase 1b open-label trial was duration and incidence of severe neutropenia in cycle 1.
Product Name : ALRN-6924
Product Type : Peptide
Upfront Cash : Inapplicable
February 21, 2023
Details:
Non-clinical data demonstrated principle that ALRN-6924 can temporarily arrest cell cycle in human scalp hair follicles and their stem cells also ALRN-6924-induced cell cycle arrest protected hair follicles from paclitaxel-induced toxicity and irreversible stem cell damage.
Lead Product(s): Sulanemadlin,Paclitaxel
Therapeutic Area: Dermatology Brand Name: ALRN-6924
Study Phase: Phase IProduct Type: Peptide
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 05, 2022
Lead Product(s) : Sulanemadlin,Paclitaxel
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Non-clinical data demonstrated principle that ALRN-6924 can temporarily arrest cell cycle in human scalp hair follicles and their stem cells also ALRN-6924-induced cell cycle arrest protected hair follicles from paclitaxel-induced toxicity and irreversib...
Product Name : ALRN-6924
Product Type : Peptide
Upfront Cash : Inapplicable
October 05, 2022
Details:
The primary endpoints are duration and incidence of severe neutropenia (Grade 4) in cycle 1. Secondary endpoints include the chemoprotective effect of ALRN-6924 on chemotherapy-induced alopecia, as well as other hematologic and non-hematologic toxicities.
Lead Product(s): Sulanemadlin
Therapeutic Area: Dermatology Brand Name: ALRN-6924
Study Phase: Phase IProduct Type: Peptide
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 30, 2022
Lead Product(s) : Sulanemadlin
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The primary endpoints are duration and incidence of severe neutropenia (Grade 4) in cycle 1. Secondary endpoints include the chemoprotective effect of ALRN-6924 on chemotherapy-induced alopecia, as well as other hematologic and non-hematologic toxicities...
Product Name : ALRN-6924
Product Type : Peptide
Upfront Cash : Inapplicable
September 30, 2022
ABOUT THIS PAGE